Article info
PDFEthics
A review of recorded information given to patients starting to take clozapine and the development of guidelines on disclosure, a key component of informed consent
- Dr Brian Parsons, Psychiatry of Old Age, North Dublin, 61 Eccles St, Dublin 7, Republic of Ireland; oapsych{at}mater.ie
Citation
A review of recorded information given to patients starting to take clozapine and the development of guidelines on disclosure, a key component of informed consent
Publication history
- Received March 31, 2006
- Revised October 11, 2006
- Accepted October 16, 2006
- First published September 28, 2007.
Online issue publication
September 28, 2007
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
2007 BMJ Publishing Group & Institute of Medical Ethics
Other content recommended for you
- Role of primary care in supporting patients who are taking clozapine
- Delaying clozapine: how long is too long?
- Patients’ and psychiatrists’ perspectives on clozapine treatment—a scoping review protocol
- Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective
- Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study
- Study protocol for the development and internal validation of Schizophrenia Prediction of Resistance to Treatment (SPIRIT): a clinical tool for predicting risk of treatment resistance to antipsychotics in first-episode schizophrenia
- Combination of strategies to initiate clozapine for refractory schizophrenia in a patient with low neutrophil levels
- Clozapine-induced pericarditis: an ethical dilemma
- Successful rechallenge with clozapine following ‘red alert’
- Leucocytosis in clozapine-treated patients as predictor of loss of treatment response?